Long-term safety data for GLP-1 receptor agonists are still being accumulated. Given their relatively recent introduction, ongoing post-market surveillance and clinical trials are essential to identify any rare or delayed adverse effects. The impact on bone density, potential immunogenicity, and effects on renal function are areas that require further investigation to fully understand the long-term safety of these agents.
